SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Alembic Pharma gets USFDA’s nod for anti-inflammatory drug: Report

26 Jun 2015 Evaluate

Alembic Pharmaceuticals has reportedly received tentative approval from US Food and Drug Administration (USFDA) for its anti-inflammatory drug. The pharma company has received tentative approval from USFDA for Celecoxib oral capsules, 50 mg, 100mg, 200 mg, 400 mg. GD Searle LLC division of Pfizer Inc is the innovator of this drug. Companies like Teva, Mylan, Watson, Lupin and Apotex have been selling Celecoxib drug, which is one of Pfizer's billion dollar drugs and has a $2 billion size.

Alembic Pharmaceuticals, a vertically integrated research and development pharmaceutical company, has been at the forefront of Healthcare since 1907. The company manufactures and markets generic pharmaceuticals products all over the world.

Alembic Pharma Share Price

759.00 -25.95 (-3.31%)
20-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1668.00
Dr. Reddys Lab 1232.25
Cipla 1228.90
Zydus Lifesciences 936.35
Lupin 2328.60
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×